Funding
← Back to your selection

EQT Life Sciences

Activity from announced rounds

Activity in this selectionOct 20, 2026 · Jul 23, 2026
Rounds participated in
2
Confirmed lead rounds
0
1 roles undisclosed
New companies
2
First participation on record · 0 follow-on
Funding in participating rounds
$152M
1 disclosed · full round size, not this investor’s share

By stage

Series B1
Series C+1

By primary sector

Biotech2

By country

Switzerland2

Rounds

2 in this selection
Nouscom

Clinical-stage biotech developing neoantigen-based cancer immunotherapies.

€120MSeries D
Participant
Vaderis Therapeutics

Develops an oral AKT inhibitor for hereditary hemorrhagic telangiectasia

$152MSeries B
Role not disclosed